Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
21.44 USD | -6.96% | -16.76% | +121.63% |
May. 16 | HC Wainwright Initiates Dianthus Therapeutics With Buy Rating, $40 Price Target | MT |
May. 10 | Wedbush Adjusts Dianthus Therapeutics' Price Target to $38 From $33, Keeps Outperform Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+121.63% | 677M | |
+10.49% | 115B | |
+12.02% | 106B | |
-6.01% | 24.69B | |
-2.33% | 21.97B | |
-6.03% | 19.27B | |
-13.53% | 17.56B | |
-40.50% | 17.32B | |
+6.57% | 14.03B | |
+30.76% | 12.13B |
- Stock Market
- Equities
- DNTH Stock
- News Dianthus Therapeutics, Inc.
- Wedbush Starts Dianthus Therapeutics With Outperform Rating, $23 Price Target; Sees DNTH103 as Promising Candidate